ASPIRIN: Neurodevelopmental Follow-up Trial | NCT04888377

NCT04888377

Status Module

Sponsor/Collaborators Module

Name	Class
Thomas Jefferson University	OTHER
RTI International	OTHER
Thrasher Research Fund	OTHER

Oversight Module

Description Module

Detailed Description

An estimated 250 million children under the age of 511 worldwide are at risk for not achieving their developmental potential; 52.9 million children under five years of age in low- and middle-income country (LMIC) settings have neurodevelopmental delays. Compounding the issue is preterm birth (more common in LMICs) which has consistently been identified as a cause of neurodevelopmental delay. A recent review reported that out of the estimated 13 million preterm infants who survive beyond the first month, 0.9 million will suffer long term neurodevelopmental impairment, with 345,000 moderately or severely affected. This burden places a significant strain on the families, healthcare systems and societies that provide care for these children. Data from other Global Network participating sites (Guatemala, Democratic Republic of Congo, Zambia and Pakistan) also found strikingly high rates of stunting ranging from 44% to 66%, among infants and toddlers. Poverty additionally contributes to the attainment of optimal neurodevelopment. As such, any study of neurodevelopment should at least document these potential confounders.

Aspirin has been shown to predominantly affect both the COX-1 pathway which is involved in thrombosis and the COX-2 pathway, which affects inflammation through the production of Aspirin Triggered Lipoxins. More specifically, aspirin has been shown to inhibit the production of IL-6, IL-1B, CRP and TNF-α all of which have been shown to negatively affect child neurodevelopment and be involved in preeclampsia and preterm birth.

This will be a prospective masked matched cohort study of children between 33 and 39 months (mean 36 months) of age whose mothers were randomized in the ASPIRIN trial *NCT02409680* (1:1 Aspirin-Placebo), who will be evaluated using the BSID-III. Additionally, the Family Resources and Context questionnaire will be performed to adjust for the local context and the ASQ-3 will be administered as a secondary screen. Recognizing the significant role that preterm birth plays in neurodevelopment, the investigators will include 100 (50 in each group) children who were delivered before 37 weeks.

Conditions Module

Design Module

Interventional Study Design

Biospecimen

No data available

No data is available for this block.

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Antenatal exposure to low dose aspirin		Mothers in the Global Networks ASPIRIN trial were given 81 mg of Aspirin throughout their pregnancy with the follow-up studies participant.	Drug: Aspirin
Antenatal exposure to Placebo		Mothers in the Global Networks ASPIRIN trial were given placebo throughout their pregnancy with the follow-up studies participant.	Drug: Placebo

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Aspirin	Drug	Participant's mothers were administered 81mg of Aspirin throughout their pregnancy with the participant.	Antenatal exposure to low dose aspirin

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Bayley Scales of Infant and Toddler Development, 3rd Edition (Bayley-III) Cognitive Composite Score	Mean of the Bayley-III Cognitive Composite Score (standardized mean 100, SD 15, range 55-155) (lower scores indicating greater impairment)	At a single visit occurring between 33-39 months corrected age

Secondary Outcomes

Measure	Description	Time Frame
Bayley Scales of Infant and Toddler Development, 3rd Edition (Bayley-III) Cognitive Composite Score Less Than 70	Number of participants with the Bayley-III Cognitive Composite score less than 70 (standardized mean 100, SD 15, range 55-155) (lower scores indicating greater impairment)	At a single visit occurring between 33-39 months corrected age

Eligibility Module

Contacts/Locations Module

Name	Affiliation	Role
Elizabeth McClure, PhD	RTI International	Principal Investigator

Facility	Status	City	State	ZIP	Country	Contacts
University of Alabama, Birmingham		Birmingham	Alabama	35233	United States
University of Colorado Health Sciences Center

References Module

Citations

PubMed Identifier	Type	Citation	Retractions
38262066	Derived	Hoffman MK, Goudar S, Dhaded S, Figueroa L, Mazariegos M, Krebs NF, Westcott J, Tikmani SS, Karim F, Saleem S, Goldenberg RL, Lokangaka A, Tshefu A, Bauserman M, Patel A, Das P, Hibberd P, Chomba E, Mwenchanya M, Carlo WA, Trotta M, Williams A, Moore J, Nolen T, Goco N, McClure EM, Lobo MA, Cunha AB, Derman RJ. Neurodevelopment of Children Whose Mothers Were Randomized to Low-Dose Aspirin During Pregnancy. Obstet Gynecol. 2024 Apr 1;143(4):554-561. doi: 10.1097/AOG.0000000000005514. Epub 2024 Jan 23.

IPD Sharing Statement Module

Results Section

Participant Flow Module

Arm/Group Information

ID	Title	Description
FG000	Aspirin	Children of mothers who received 81mg low-dose aspirin daily beginning between 6 weeks 0 days and 13 weeks 6 days, until 37 weeks or delivery.
FG001	Placebo	Children of mothers who received placebo daily beginning between 6 weeks 0 days and 13 weeks 6 days, until 37 weeks or delivery.

Baseline Characteristics Module

Outcome Measures Module

Adverse Events Module

More Info Module

Annotation Section

No data available

No data is available for this block.

Document Section

Large Document Module

Uploaded Document Information

Type	Includes Protocol	Includes SAP	Includes ICF	Document Label	Document Date	Document Uploaded Date	Document File Name
Prot_SAP	Yes	Yes	No	Study Protocol and Statistical Analysis Plan	Jul 30, 2021

Derived Section

Miscellaneous Info Module

Submission Tracking

No data available

No data is available for this block.

Condition Browse Module

Intervention Browse Module

Masking Info

No data available

No data is available for this block.

Type of Units Analyzed

Arm/Group Information

ID	Title	Description
BG000	Aspirin	Children of mothers who received 81mg low-dose aspirin daily beginning between 6 weeks 0 days and 13 weeks 6 days, until 37 weeks or delivery.
BG001	Placebo	Children of mothers who received placebo daily beginning between 6 weeks 0 days and 13 weeks 6 days, until 37 weeks or delivery.
BG002	Total	Total of all reporting groups

Baseline Measures

Title

Description

Population Description

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Denominator Units Selected

Denominators

Classes

Age, Continuous

Age refers to the child at screening and is measured in months

Mean

Standard Deviation

months

Title

Denominators

Categories

Title	Measurements
	BG00037.5± 1 BG00137.5± 0.9 BG00237.5± 0.9

Sex: Female, Male

Count of Participants

Participants

Title

Denominators

Categories

Title	Measurements
Female	BG000173 BG001155 BG002

Race/Ethnicity, Customized

Race

Count of Participants

Participants

Title

Denominators

Categories

Title	Measurements
American Indian or Alaska Native	BG00071 BG00165 BG002

Race/Ethnicity, Customized

Ethnicity

Count of Participants

Participants

Title

Denominators

Categories

Title	Measurements
Hispanic or Latino	BG00071 BG00165 BG002

Maternal education

Maternal education categories

Count of Participants

Participants

Title

Denominators

Categories

Title	Measurements
No formal schooling	BG00052 BG00144 BG002

Type

Title

Description

Population Description

Reporting Status

Anticipated Posting Date

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Time Frame

Units Analyzed

Denominator Units Selected

Arm/Group Information

Denominators

Classes

Analyses

Primary

Bayley Scales of Infant and Toddler Development, 3rd Edition (Bayley-III) Cognitive Composite Score

Mean of the Bayley-III Cognitive Composite Score (standardized mean 100, SD 15, range 55-155) (lower scores indicating greater impairment)

The analysis population includes all randomized infants with available data for the primary outcome.

Posted

Mean

Standard Deviation

score on a scale

At a single visit occurring between 33-39 months corrected age

ID	Title	Description
OG000	Aspirin	Children of mothers who received 81mg low-dose aspirin daily beginning between 6 weeks 0 days and 13 weeks 6 days, until 37 weeks or delivery.
OG001	Placebo	Children of mothers who received placebo daily beginning between 6 weeks 0 days and 13 weeks 6 days, until 37 weeks or delivery.

Units	Counts
Participants	OG000329 OG001311

Title

Denominators

Categories

Title	Measurements
	OG00096± 9.9 OG00196.8± 10.4

Group IDs	Group Description	Statistical Method	Statistical Comment	P-Value	P-Value Comment	Parameter Type	Parameter Value	Dispersion Type	Dispersion Value	Confidence Interval Sides	Confidence Interval %	CI Lower Limit	CI Upper Limit	CI Lower Limit Comment	CI Upper Limit Comment	Estimate Comment	Tested Non-Inferiority	Non-Inferiority Type	Non-Inferiority Comment	Other Analysis Description
OG000 OG001	Assuming a non-inferiority margin of 4 points in the BSID-III cognitive score as clinically significant, and a true effect of LDA of not more than a 1 point decrease, a total sample size of 620 was determined to provide 80% power for a one-sided test for non-inferiority with a type I error of 5%. To test this secondary hypothesis, the sample size also provided over 90% power, at a two-sided type I error of 5%, to detect a difference of 4 points between LDA and placebo based on a two-sided test.	ANCOVA		0.25	For each outcome, the adjusted mean difference between treatment groups and the associated 95% confidence interval based on an ANCOVA model is presented.	Mean Difference (Final Values)	-0.8			2-Sided	95	-2.2	0.6			Mean difference is Aspirin-Placebo.

Secondary

Bayley Scales of Infant and Toddler Development, 3rd Edition (Bayley-III) Cognitive Composite Score Less Than 70

Number of participants with the Bayley-III Cognitive Composite score less than 70 (standardized mean 100, SD 15, range 55-155) (lower scores indicating greater impairment)

The analysis population includes all randomized infants with available data for the primary outcome.

Posted

Count of Participants

Participants

At a single visit occurring between 33-39 months corrected age

ID	Title	Description
OG000	Aspirin	Children of mothers who received 81mg low-dose aspirin daily beginning between 6 weeks 0 days and 13 weeks 6 days, until 37 weeks or delivery.
OG001	Placebo	Children of mothers who received placebo daily beginning between 6 weeks 0 days and 13 weeks 6 days, until 37 weeks or delivery.

Units	Counts
Participants	OG000

Secondary

Bayley Scales of Infant and Toddler Development, 3rd Edition (Bayley-III) Cognitive Composite Score Less Than 1 Standard Deviation (SD) Below the Mean

Number of participants with the Bayley-III Cognitive Composite score less than 1 SD below the sample mean (standardized mean 100, SD 15, range 55-155) (lower scores indicating greater impairment)

The analysis population includes all randomized infants with available data for the primary outcome.

Posted

Count of Participants

Participants

At a single visit occurring between 33-39 months corrected age

ID	Title	Description
OG000	Aspirin	Children of mothers who received 81mg low-dose aspirin daily beginning between 6 weeks 0 days and 13 weeks 6 days, until 37 weeks or delivery.
OG001	Placebo	Children of mothers who received placebo daily beginning between 6 weeks 0 days and 13 weeks 6 days, until 37 weeks or delivery.

Units	Counts
Participants	OG000

Secondary

Bayley Scales of Infant and Toddler Development, 3rd Edition (Bayley-III) Language Composite Score

Mean of the Bayley-III Language Composite Score (standardized mean 100, SD 15, range 45-155) (lower scores indicating greater impairment)

The analysis population includes all randomized infants with available data for the primary outcome.

Posted

Mean

Standard Deviation

score on a scale

At a single visit occurring between 33-39 months corrected age

ID	Title	Description
OG000	Aspirin	Children of mothers who received 81mg low-dose aspirin daily beginning between 6 weeks 0 days and 13 weeks 6 days, until 37 weeks or delivery.
OG001	Placebo	Children of mothers who received placebo daily beginning between 6 weeks 0 days and 13 weeks 6 days, until 37 weeks or delivery.

Units	Counts
Participants	OG000

Secondary

Bayley Scales of Infant and Toddler Development, 3rd Edition (Bayley-III) Language Composite Score Less Than 70

Number of participants with the Bayley-III Language Composite score less than 70 (standardized mean 100, SD 15, range 45-155) (lower scores indicating greater impairment)

The analysis population includes all randomized infants with available data for the primary outcome.

Posted

Count of Participants

Participants

At a single visit occurring between 33-39 months corrected age

ID	Title	Description
OG000	Aspirin	Children of mothers who received 81mg low-dose aspirin daily beginning between 6 weeks 0 days and 13 weeks 6 days, until 37 weeks or delivery.
OG001	Placebo	Children of mothers who received placebo daily beginning between 6 weeks 0 days and 13 weeks 6 days, until 37 weeks or delivery.

Units	Counts
Participants	OG000

Secondary

Bayley Scales of Infant and Toddler Development, 3rd Edition (Bayley-III) Language Composite Score Less Than 1 Standard Deviation (SD) Below the Mean

Number of participants with the Bayley-III Language Composite score less than 1 SD below the sample mean (standardized mean 100, SD 15, range 45-155) (lower scores indicating greater impairment)

The analysis population includes all randomized infants with available data for the primary outcome.

Posted

Count of Participants

Participants

At a single visit occurring between 33-39 months corrected age

ID	Title	Description
OG000	Aspirin	Children of mothers who received 81mg low-dose aspirin daily beginning between 6 weeks 0 days and 13 weeks 6 days, until 37 weeks or delivery.
OG001	Placebo	Children of mothers who received placebo daily beginning between 6 weeks 0 days and 13 weeks 6 days, until 37 weeks or delivery.

Units	Counts
Participants	OG000

Secondary

Bayley Scales of Infant and Toddler Development, 3rd Edition (Bayley-III) Motor Composite Score

Mean of the Bayley-III Motor Composite Score (standardized mean 100, SD 15, range 45-155) (lower scores indicating greater impairment)

The analysis population includes all randomized infants with available data for the primary outcome.

Posted

Mean

Standard Deviation

score on a scale

At a single visit occurring between 33-39 months corrected age

ID	Title	Description
OG000	Aspirin	Children of mothers who received 81mg low-dose aspirin daily beginning between 6 weeks 0 days and 13 weeks 6 days, until 37 weeks or delivery.
OG001	Placebo	Children of mothers who received placebo daily beginning between 6 weeks 0 days and 13 weeks 6 days, until 37 weeks or delivery.

Units	Counts
Participants	OG000

Secondary

Bayley Scales of Infant and Toddler Development, 3rd Edition (Bayley-III) Motor Composite Score Less Than 70

Number of participants with the Bayley-III Motor Composite score less than 70 (standardized mean 100, SD 15, range 45-155) (lower scores indicating greater impairment)

The analysis population includes all randomized infants with available data for the primary outcome.

Posted

Count of Participants

Participants

At a single visit occurring between 33-39 months corrected age

ID	Title	Description
OG000	Aspirin	Children of mothers who received 81mg low-dose aspirin daily beginning between 6 weeks 0 days and 13 weeks 6 days, until 37 weeks or delivery.
OG001	Placebo	Children of mothers who received placebo daily beginning between 6 weeks 0 days and 13 weeks 6 days, until 37 weeks or delivery.

Units	Counts
Participants	OG000

Secondary

Bayley Scales of Infant and Toddler Development, 3rd Edition (Bayley-III) Motor Composite Score Less Than 1 Standard Deviation (SD) Below the Mean

Number of participants with the Bayley-III Motor Composite score less than 1 SD below the sample mean (standardized mean 100, SD 15, range 45-155) (lower scores indicating greater impairment)

The analysis population includes all randomized infants with available data for the primary outcome.

Posted

Count of Participants

Participants

At a single visit occurring between 33-39 months corrected age

ID	Title	Description
OG000	Aspirin	Children of mothers who received 81mg low-dose aspirin daily beginning between 6 weeks 0 days and 13 weeks 6 days, until 37 weeks or delivery.
OG001	Placebo	Children of mothers who received placebo daily beginning between 6 weeks 0 days and 13 weeks 6 days, until 37 weeks or delivery.

Units	Counts
Participants	OG000

Secondary

Ages and Stages Questionnaire, 3rd Edition (ASQ-3) Communication Total Score

Mean of the ASQ Communication Total Score (range 0-60) (lower scores indicating greater impairment)

The analysis population includes all randomized infants with available data for the primary outcome.

Posted

Mean

Standard Deviation

score on a scale

At a single visit occurring between 33-39 months corrected age

ID	Title	Description
OG000	Aspirin	Children of mothers who received 81mg low-dose aspirin daily beginning between 6 weeks 0 days and 13 weeks 6 days, until 37 weeks or delivery.
OG001	Placebo	Children of mothers who received placebo daily beginning between 6 weeks 0 days and 13 weeks 6 days, until 37 weeks or delivery.

Units	Counts
Participants	OG000

Secondary

Ages and Stages Questionnaire, 3rd Edition (ASQ-3) Communication Total Score Less Than 1 Standard Deviation (SD) Below the Mean

Number of participants with the ASQ Communication Total score less than 1 SD below the sample mean (range 0-60) (lower scores indicating greater impairment)

The analysis population includes all randomized infants with available data for the primary outcome.

Posted

Count of Participants

Participants

At a single visit occurring between 33-39 months corrected age

ID	Title	Description
OG000	Aspirin	Children of mothers who received 81mg low-dose aspirin daily beginning between 6 weeks 0 days and 13 weeks 6 days, until 37 weeks or delivery.
OG001	Placebo	Children of mothers who received placebo daily beginning between 6 weeks 0 days and 13 weeks 6 days, until 37 weeks or delivery.

Units	Counts
Participants	OG000

Secondary

Ages and Stages Questionnaire, 3rd Edition (ASQ-3) Gross Motor Total Score

Mean of the ASQ Gross Motor Total Score (range 0-60) (lower scores indicating greater impairment)

The analysis population includes all randomized infants with available data for the primary outcome.

Posted

Mean

Standard Deviation

score on a scale

At a single visit occurring between 33-39 months corrected age

ID	Title	Description
OG000	Aspirin	Children of mothers who received 81mg low-dose aspirin daily beginning between 6 weeks 0 days and 13 weeks 6 days, until 37 weeks or delivery.
OG001	Placebo	Children of mothers who received placebo daily beginning between 6 weeks 0 days and 13 weeks 6 days, until 37 weeks or delivery.

Units	Counts
Participants	OG000

Secondary

Ages and Stages Questionnaire, 3rd Edition (ASQ-3) Gross Motor Total Score Less Than 1 Standard Deviation (SD) Below the Mean

Number of participants with the ASQ Gross Motor Total score less than 1 SD below the sample mean (range 0-60) (lower scores indicating greater impairment)

The analysis population includes all randomized infants with available data for the primary outcome.

Posted

Count of Participants

Participants

At a single visit occurring between 33-39 months corrected age

ID	Title	Description
OG000	Aspirin	Children of mothers who received 81mg low-dose aspirin daily beginning between 6 weeks 0 days and 13 weeks 6 days, until 37 weeks or delivery.
OG001	Placebo	Children of mothers who received placebo daily beginning between 6 weeks 0 days and 13 weeks 6 days, until 37 weeks or delivery.

Units	Counts
Participants	OG000

Secondary

Ages and Stages Questionnaire, 3rd Edition (ASQ-3) Fine Motor Total Score

Mean of the ASQ Fine Motor Total Score (range 0-60) (lower scores indicating greater impairment)

The analysis population includes all randomized infants with available data for the primary outcome.

Posted

Mean

Standard Deviation

score on a scale

At a single visit occurring between 33-39 months corrected age

ID	Title	Description
OG000	Aspirin	Children of mothers who received 81mg low-dose aspirin daily beginning between 6 weeks 0 days and 13 weeks 6 days, until 37 weeks or delivery.
OG001	Placebo	Children of mothers who received placebo daily beginning between 6 weeks 0 days and 13 weeks 6 days, until 37 weeks or delivery.

Units	Counts
Participants	OG000

Secondary

Ages and Stages Questionnaire, 3rd Edition (ASQ-3) Fine Motor Total Score Less Than 1 Standard Deviation (SD) Below the Mean

Number of participants with the ASQ Fine Motor Total score less than 1 SD below the sample mean (range 0-60) (lower scores indicating greater impairment)

The analysis population includes all randomized infants with available data for the primary outcome.

Posted

Count of Participants

Participants

At a single visit occurring between 33-39 months corrected age

ID	Title	Description
OG000	Aspirin	Children of mothers who received 81mg low-dose aspirin daily beginning between 6 weeks 0 days and 13 weeks 6 days, until 37 weeks or delivery.
OG001	Placebo	Children of mothers who received placebo daily beginning between 6 weeks 0 days and 13 weeks 6 days, until 37 weeks or delivery.

Units	Counts
Participants	OG000

Secondary

Ages and Stages Questionnaire, 3rd Edition (ASQ-3) Problem Solving Total Score

Mean of the ASQ Problem Solving Total Score (range 0-60) (lower scores indicating greater impairment)

The analysis population includes all randomized infants with available data for the primary outcome.

Posted

Mean

Standard Deviation

score on a scale

At a single visit occurring between 33-39 months corrected age

ID	Title	Description
OG000	Aspirin	Children of mothers who received 81mg low-dose aspirin daily beginning between 6 weeks 0 days and 13 weeks 6 days, until 37 weeks or delivery.
OG001	Placebo	Children of mothers who received placebo daily beginning between 6 weeks 0 days and 13 weeks 6 days, until 37 weeks or delivery.

Units	Counts
Participants	OG000

Secondary

Ages and Stages Questionnaire, 3rd Edition (ASQ-3) Problem Solving Total Score Less Than 1 Standard Deviation (SD) Below the Mean

Number of participants with the ASQ Problem Solving Total score less than 1 SD below the sample mean (range 0-60) (lower scores indicating greater impairment)

The analysis population includes all randomized infants with available data for the primary outcome.

Posted

Count of Participants

Participants

At a single visit occurring between 33-39 months corrected age

ID	Title	Description
OG000	Aspirin	Children of mothers who received 81mg low-dose aspirin daily beginning between 6 weeks 0 days and 13 weeks 6 days, until 37 weeks or delivery.
OG001	Placebo	Children of mothers who received placebo daily beginning between 6 weeks 0 days and 13 weeks 6 days, until 37 weeks or delivery.

Units	Counts
Participants	OG000

Secondary

Ages and Stages Questionnaire, 3rd Edition (ASQ-3) Personal Social Total Score

Mean of the ASQ Personal Social Total Score (range 0-60) (lower scores indicating greater impairment)

The analysis population includes all randomized infants with available data for the primary outcome.

Posted

Mean

Standard Deviation

score on a scale

At a single visit occurring between 33-39 months corrected age

ID	Title	Description
OG000	Aspirin	Children of mothers who received 81mg low-dose aspirin daily beginning between 6 weeks 0 days and 13 weeks 6 days, until 37 weeks or delivery.
OG001	Placebo	Children of mothers who received placebo daily beginning between 6 weeks 0 days and 13 weeks 6 days, until 37 weeks or delivery.

Units	Counts
Participants	OG000

Secondary

Ages and Stages Questionnaire, 3rd Edition (ASQ-3) Personal Social Total Score Less Than 1 Standard Deviation (SD) Below the Mean

Number of participants with the ASQ Personal Social Total score less than 1 SD below the sample mean (range 0-60) (lower scores indicating greater impairment)

The analysis population includes all randomized infants with available data for the primary outcome.

Posted

Count of Participants

Participants

At a single visit occurring between 33-39 months corrected age

ID	Title	Description
OG000	Aspirin	Children of mothers who received 81mg low-dose aspirin daily beginning between 6 weeks 0 days and 13 weeks 6 days, until 37 weeks or delivery.
OG001	Placebo	Children of mothers who received placebo daily beginning between 6 weeks 0 days and 13 weeks 6 days, until 37 weeks or delivery.

Units	Counts
Participants	OG000

Arm/Groups

ID	Title	Description	Deaths (Affected)	Deaths (At Risk)	Serious Events (Affected)	Serious Events (At Risk)	Other Events (Affected)	Other Events (At Risk)
EG000	Aspirin	Children of mothers who received 81mg low-dose aspirin daily beginning between 6 weeks 0 days and 13 weeks 6 days, until 37 weeks or delivery.	0	329	0	329	0	329
EG001	Placebo	Children of mothers who received placebo daily beginning between 6 weeks 0 days and 13 weeks 6 days, until 37 weeks or delivery.	0	311	0	311	0	311

ID	Term
D011225	Pre-Eclampsia

ID	Term
D001241	Aspirin

Ancestor Terms

ID	Term
D012459	Salicylates
D062385	Hydroxybenzoates
D010636	Phenols
D001555	Benzene Derivatives
D006841	Hydrocarbons, Aromatic
D006844	Hydrocarbons, Cyclic
D006838	Hydrocarbons
D009930	Organic Chemicals

ID	Term
D046110	Hypertension, Pregnancy-Induced
D011248	Pregnancy Complications
D005261	Female Urogenital Diseases and Pregnancy Complications
D000091642	Urogenital Diseases